Chemotherapy & Immunotherapy Quality

• 2,159 DKG-certified cancer facilities (as of December 2024) including 15 CCCs; mandatory multidisciplinary tumor boards at all certified centers [Zertifizierung - Deutsche Krebsgesellschaft - 2024]
• Five-year survival rates exceed international benchmarks: breast cancer 86% (EU average 82%), colon cancer 64.8% (OECD 62.1%), prostate cancer 91–94% early-stage, childhood ALL 91.8% [EU Country Cancer Profile Germany 2025 - OECD - 2025]
• Drug access speed of 133 days from EMA authorization to patient availability — fastest in Europe under AMNOG system [Impact of AMNOG on launch delays - PMC - 2023]
• CAR-T cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel, BCMA-directed) available at ≥5 university centers and covered by statutory health insurance [CAR-T Cell Therapy in Germany - car-t-access.org - 2024]
• Comprehensive medical tourism infrastructure with dedicated international patient offices at Charité, LMU Munich, and Heidelberg; 24/7 English interpretation; appointments coordinated within 24 hours [Cancer Treatment in Germany for Foreigners - Cancer Rounds - 2024]

Read the full Germany report →

• 73 NCI-Designated Cancer Centers in 37 states, including 58 Comprehensive Cancer Centers, representing the top 4% of approximately 1,500 cancer centers in the United States, with ~400,000 patients receiving diagnoses annually
• 6 FDA-approved CAR-T cell therapies as of December 2024, comprehensive immunotherapy portfolio including PD-1, PD-L1, and CTLA-4 inhibitors, and precision medicine programs operational
• 70% five-year relative survival for all cancers combined (2015-2021), with regional-stage disease at 69% and myeloma at 62%, representing significant improvements from mid-1990s baselines (63%, 54%, and 32% respectively)
• FDA issued 60+ oncology approvals in 2024 including 11 first-in-class therapeutics, providing rapid patient access to innovations within months of approval
• NCCN Clinical Practice Guidelines recognized as the global standard for cancer treatment protocols, applied to 97% of US cancer patients and acknowledged as the most thorough and frequently updated guidelines available
• ABIM board certification as the widely-used standard for medical oncologists, requiring fellowship training in medical oncology plus internal medicine certification, with NCI centers serving as centers for scientific leadership and international research collaborations

Read the full United States report →

• Breast cancer 5-year survival at 89%, comparable to Australia (89.5%) and Canada (88.2%), exceeding Score 5 threshold of >80%
• Multiple internationally accredited centers including ESMO-accredited Burjeel Cancer Institute with JCI, TEMOS, CAP, CARF, EBMT, and ISO 9001:2015 certifications
• CAR-T cell therapy domestically manufactured at ADSCC (FACT-accredited April 2024) and Burjeel (2025), with precision medicine and tumor biomarker testing at leading centers
• Newly approved FDA/EMA drugs available within 12-18 months via EDE 25-working-day fast-track approval pathway
• TEMOS-accredited medical tourism programs with multilingual oncology teams and concierge services; international patients from Saudi Arabia, Kuwait, India, Nigeria, Ethiopia, Russia, and Kazakhstan

Read the full United Arab Emirates report →

• Spain operates 28 AEMPS-accredited CAR-T centers with Hospital Clínic treating >500 patients and achieving 90% response rate in ALL, 60% in myeloma
• Two OECI-accredited Comprehensive Cancer Centres (Vall d'Hebron and Clínic Barcelona) with 18 OECI-member institutions total
• 5-year survival rates: breast cancer 85.5%, prostate 89.6%, colorectal 65% (colorectal exceeds EU-24 average of 60%)
• Led EU with 336 oncology clinical trials authorized in 2024, providing access to novel agents before formal EMA approval
• Hospital-developed CAR-T (ARI-0001, ARI-0002h) cost under €90,000 versus ~€400,000 commercial alternatives
• Established medical tourism programs: MD Anderson Madrid (only European affiliate), Hospital Ruber Internacional (24/7 multilingual, IMTJ award), Clínica Universidad de Navarra (JCI since 2004, Newsweek Top 35)

Read the full Spain report →

• 408 designated cancer care hospitals with mandated chemotherapy centers; NCC Hospital East holds ESMO Centre of Integrated Oncology designation; NCC Hospital named 'World's Best Specialized Hospitals 2021' by Newsweek
• Comprehensive approved therapies: multiple checkpoint inhibitors (nivolumab, pembrolizumab, durvalumab, ipilimumab, atezolizumab), full range of targeted therapies (ALK/EGFR/RET/MET/KRAS/HER2 inhibitors, antibody-drug conjugates), and all three FDA-approved CAR-T therapies (Kymriah, Yescarta, Abecma)
• 1,604 JSMO-certified medical oncologists as of 2022, up from 867 in 2013; structured 3-year fellowships with international training; 53.7% of DCCHs have dedicated medical oncology departments with JSMO-certified specialists
• Five-year survival rates: breast 87.5%, prostate 99.2%, colorectal 69.7%; CONCORD-3 study shows stomach cancer 60.3% net survival (2010-14), improving from 50.5% (2000-04), outperforming Western peers
• National cancer genomic medicine program across 260 hospitals with insurance-reimbursed comprehensive genomic profiling; C-CAT datacenter provides standardized expert panel recommendations; 45-59% of advanced patients have actionable mutations detected
• Formal international patient programs at NCC Hospital through seven coordinating agencies offering multilingual support; median drug approval lag of 1,278 days post-US approval (2011-2022 historical data) but shorter for immunotherapy and narrowing with recent PMDA reforms

Read the full Japan report →

• MSCNRIO Warsaw holds ESMO Designated Centre status, manages 25% of Polish cancer patients with 650+ clinical trials; Gliwice branch operates a Molecular Laboratory recognized as Centre of Excellence with 120+ past clinical trials
• Multiple checkpoint inhibitors reimbursed since 2018 (nivolumab, pembrolizumab) with 63 new oncology indications added to reimbursement list in 2025; standard chemotherapy universally available under NFZ
• Breast cancer 5-year survival 80% and prostate cancer 85.2% meet international benchmarks; overall national rate 42.7% vs. EU 54.6%; documented improving trend across major cancer types
• Median 27-month delay from EMA approval to reimbursement; precision medicine integration via Oncotype DX (changed treatment decisions in 44.3% of patients), NGS-based molecular profiling, and mandatory multidisciplinary tumor boards at SOLO II/III centers
• Private medical tourism centers (Carolina Medical Center, KCM Clinic ISO-certified, Medicover) offer English-language oncology services at 50-80% below US costs with organized international patient coordination

Read the full Poland report →

• The Christie re-accredited as OECI Comprehensive Cancer Centre in February 2025 (status to July 2030); Royal Marsden rated 'Outstanding' by Care Quality Commission
• Cancer Drugs Fund provides access to 100+ drugs across 250 indications approximately 6 months faster than standard regulatory processes; NICE-approved CAR-T (obe-cel) achieved 74.7% remission rate in 127 patients with relapsed/refractory B-ALL
• Overall 5-year cancer survival improved from 47.9% (2005 cohort) to 55.7% (2016 cohort); prostate cancer 88.5%, melanoma 92.6%, testicular 93.5%, but lung and stomach cancer rank 28th of 33 comparable nations with combined 16% survival
• Medical oncologists complete 2-year MRCP training plus 4-year specialty training with mandatory Specialty Certificate Examination; however, 15% deficit in clinical oncologists in 2024, projected to reach 19% by 2029
• Comprehensive private medical tourism infrastructure through Royal Marsden Private Care, HCA Healthcare UK, London Clinic, and Cromwell Hospital with multilingual support and dedicated international patient services; 810,000 genomic tests in 2024 integrating precision medicine into routine care

Read the full United Kingdom report →

• Multiple JCI-accredited centers including Samitivej, Bumrungrad, and Bangkok Hospital's Wattanosoth Cancer Hospital with comprehensive systemic therapy programs
• Thai oncologists trained internationally at Harvard, Oxford, and University of Toronto with certifications from American Board of Internal Medicine or European Society for Medical Oncology
• CAR-T cell manufacturing capabilities operational at Siriraj Hospital (GMP-compliant closed system with nine clinical-grade products) and Cell and Gene Therapy Manufacturing Center at Chulalongkorn University (first FDA-certified facility in Thailand)
• Nivolumab and pembrolizumab checkpoint inhibitors approved by both US and Thai FDA; genetic testing available in 1 week for single-gene and 3 weeks for NGS gene panels
• Colorectal cancer 5-year survival rates for advanced stages below 50% (below international 65% threshold for advanced treatable cancers); breast cancer 5-year survival in Northeast Thailand 42.9% (significantly below international standards), though overall breast cancer survival approximately 80%
• Access disparities: high-cost immunotherapy and targeted therapy available primarily to private-pay patients; public insurance schemes lack reimbursement coverage with approval lags of 2-3+ years behind international approval
• Extensive medical tourism infrastructure with 520,000+ international patients at Bumrungrad annually, multilingual support in 20+ languages, and ranking as #5 global medical tourism destination

Read the full Thailand report →

• Hospital Israelita Albert Einstein and Hospital Sírio-Libanês ranked #19 and #20 globally in oncology by Newsweek 2025
• ANVISA approved 68 of 104 FDA oncology drugs (2008–2023) with 558-day median approval lag; pembrolizumab has 36 ANVISA approvals but only 1 covered by public health system
• 5-year breast cancer survival: 80.6% in private sector (exceeds >80% international benchmark), 68.5% in public sector; gastric cancer improved from 27.8% to 53.9% at major centers
• Hospital Sírio-Libanês International Patient Service Center provides services in 4 languages and coordinates with 70+ international insurers; Brazilian treatment costs 50–70% lower than US equivalents
• CAR-T therapy remains investigational and trial-based; INCA-CHOP partnership and local manufacturing initiatives underway but not yet operationally available as routine service; geographic concentration creates systemic access barriers with only 4% of cancer centers in the North

Read the full Brazil report →

• Multiple internationally accredited centers: Beacon Hospital and Sunway Cancer Centre hold ESMO Designated Centre status; SJMC is the first Asia-Pacific hospital with ACHSI Centre of Excellence certification for oncology; KPJ Damansara joined Mayo Clinic Care Network (February 2024) for live multidisciplinary case conferences
• Comprehensive systemic therapy availability: Standard chemotherapy (platinum, anthracyclines, taxanes), targeted therapies (HER2, EGFR), and immune checkpoint inhibitors (pembrolizumab, nivolumab) available at private centers; ICIs not covered by government UHC but accessible in private sector
• Well-trained oncology workforce: 184 oncologists as of 2025; private hospital physicians hold FRCR (UK) credentials and complete international fellowships; Master of Clinical Oncology program established since 2002
• Mixed survival outcomes: One tertiary hospital reports 46.5% five-year colorectal cancer survival; breast cancer 88% five-year in private sector (exceeds early-stage benchmarks); national figures artificially depressed by late-stage diagnosis (60%+ at stages III-IV)
• Excellent medical tourism infrastructure: 1.85 million medical tourists in 2025; Prince Court serves 140+ nationalities with multilingual coordinators; comprehensive support (airport transfers, visa assistance, hotel partnerships, currency exchange, post-departure telemedicine)
• Innovation in CAR-T and precision medicine: Domestically manufactured CAR-T at UKM delivered 100% complete response in B-ALL with 0% neurotoxicity; GMP CAR-T laboratory opened at UMMC April 2024; NGS precision oncology embedded at major centers (SJMC, Klang Valley hospitals)

Read the full Malaysia report →

• CAR-T cell therapy: NexCAR19 approved October 2023 (first domestically-developed CAR-T in LMIC), available at 30+ hospitals across 10+ cities at ~$50,000 vs $400,000 in US; second CAR-T product Qartemi also approved
• JCI accreditation: India has 55 JCI-accredited hospitals; Apollo achieved 7th JCI reaccreditation March 2024; Apollo Proton Cancer Centre 2nd JCI reaccreditation June 2023
• Survival rates: Hospital-based at TMH 70%+ overall cure rates and 65% 5-year oral cancer survival; population-level breast cancer 66.1% (below Score 4's 70-80% threshold but approaching); blood cancer remission 60-70%
• Medical oncology training: Well-structured 3-year DM super-specialty requiring MD/DNB completion and NEET-SS national entrance; many oncologists trained at US, UK, or European institutions
• Precision medicine operational: FoundationOne CDx NGS available, Apollo's molecular tumor boards established, ctDNA liquid biopsy offered at Tata Memorial since 2020
• Medical tourism infrastructure: Dedicated international patient departments at major centers, fluent English-speaking oncologists, 60-80% cost savings vs Western countries, listed as top destination for African cancer patients
• Checkpoint inhibitor access limitation: Despite availability since 2015, only 2.83% of eligible patients received immunotherapy at major tertiary center (6.6% private patients vs 0.29% low-income patients showing 23-fold disparity)
• Oncologist shortage: Approximately 1 medical oncologist per 1 million population vs 161 per million in US; systemic therapy often delivered by non-specialists outside major centers

Read the full India report →

• NIO is the first and only OECI-accredited Comprehensive Cancer Center in Central and Eastern Europe with ESGO accreditation for gynecological oncology and Breast Centres Network membership
• CAR-T cell therapy is not systematically reimbursed in Hungary with median access time of 52.3 months—among the slowest in Europe; Hungary and Malta are the only EU member states without systematic CAR-T reimbursement
• Pembrolizumab (Keytruda) automatic reimbursement covers only 38.5% of EU-approved indications versus EU average of 59%; individual approval process averages 36 days but can reach 441 days
• 5-year net survival improved 2011–2019 across all major cancer types: breast 86.84%, prostate 89.76%, colorectal 59.78%, lung 23.55%—exceeding Score 3 for early-stage but falling below Score 4 for advanced cancers
• Hungary's National Molecular Tumor Board evaluates 10–15 comprehensive genomic profiling cases weekly with 45% showing clinically actionable alterations; NGS available at NIO, Semmelweis University, and University of Pécs
• Medical tourism infrastructure includes 2,094 coordinated oncology cases via Bookimed, English and German-speaking oncology staff at major facilities, and treatment costs 35–60% below Western European levels

Read the full Hungary report →

• KHCC early-stage breast cancer survival exceeds international benchmarks: 96% (stage I), 91.3% (stage II), 75.7% (stage III)
• KHCC holds JCI disease-specific cancer center accreditation (first in developing world, sixth globally), MAGNET nursing accreditation, and CAP accreditation
• Medical oncology fellows ranked first among North American-affiliated programs in 2019 ASCO examination; international rotations at MD Anderson, Princess Margaret, Leeds Cancer Centre
• Advanced NSCLC immunotherapy median overall survival 11.8 months (244 patients 2017-2022), substantially below 16-20+ month trial benchmarks; 21% died within 3 months of initiating treatment
• Single institution dependence: KHCC handles 60%+ of Jordan's cancer cases; comprehensive systemic oncology (immunotherapy programs, precision medicine, multidisciplinary tumor boards) essentially unavailable outside KHCC
• CAR-T cell therapy listed as goal but not yet operational; GMP laboratory establishment and CAR-T initiation are stated objectives only
• HTA program approved >70% of novel cancer drug requests after price negotiations; pembrolizumab and nivolumab available
• Dedicated medical tourism infrastructure: 224,000+ medical tourists to Jordan in 2024; 25-40% cost advantage vs. US/Europe; multilingual support (English, French, Kurdish, Arabic); telemedicine follow-up
• NGS costs approximately $2,820 per test (>50% of Jordan's GDP per capita); 19.1% of patients with actionable mutations unable to access matched therapies due to cost/unavailability

Read the full Jordan report →

• Multiple JCI-accredited comprehensive cancer centers in major cities (Mexico City, Monterrey, Tijuana, Guadalajara) with 172 inpatient beds at INCan alone
• Drug approval delays of 1-3 years behind FDA for new indications and combination therapies, with COFEPRIS requiring more exhaustive phase III data
• Five-year survival rates: breast cancer 72% overall (90% early-stage, 33% metastatic), colorectal cancer 50% with 80% diagnosed in advanced stages
• Significant oncologist workforce shortage with approximately 1 medical oncologist per 136,000 Mexicans, below optimal ratios
• CAR-T therapy pioneering at only 3 institutions (UANL Monterrey, Centro Médico ABC, Hospital Ángeles) with 9 total HSCT-accredited pediatric centers
• Excellent medical tourism infrastructure with bilingual support, concierge services, and cost savings of 50-70% on cancer treatments

Read the full Mexico report →

• CTIC ($400M investment, opened 2022) operates 56 chemotherapy chairs, 12 specialized clinical units, 176 patient rooms, and intensive care backup across Bogotá, Medellín, Cali, and Bucaramanga
• Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab) approved by INVIMA from 2016–2022; combination chemo-immunotherapy protocols approved 2020+
• INC OECI member since 2018 and participates in SWOG cooperative trials; Colombia's first in-situ comprehensive genomic profiling program (2023–2024) found actionable mutations in 76.7% of tested cases
• Breast cancer 5-year survival 70.8–81.1% in Cali (improving trend over 20 years); however, colorectal cancer 45.8%, lung/stomach <25%, childhood cancer 51%—all below high-income benchmarks
• Approximately 324 medical oncology specialists nationally (deficit of 125–179 to meet international standards); 6 accredited training programs producing only 5–10 graduates annually
• Six JCI-accredited hospitals with established medical tourism programs; received 200,000+ international patients annually in 2024; Fundación Santa Fe maintains 100+ international agreements

Read the full Colombia report →

• 50+ JCI-accredited clinics with Anadolu Medical Center OECI-accredited (only 30 centers worldwide)
• Breast cancer 5-year survival 86% exceeds Score 4 benchmark (70-80%), but pancreatic 10.4% and lung cancer 14.9% survival rates fall well below Score 4 standard (50-65% for advanced cancers)
• No commercial CAR-T therapy available for standard use; ISIKOK-19 remains in clinical trial phase with 72% response rate in pilot study
• Market authorization timelines exceed FDA/EMA by 50%+ (estimated 2-3 years vs. 18-24 month Score 4 standard); regulatory barriers deterring new drug submissions
• Excellent medical tourism infrastructure: 1.8 million medical travelers in 2023, 700,000+ international patients annually, multilingual staff, treatment within 3-5 days

Read the full Turkey report →